Aldeyra Therapeutics, Inc. (ALDX) EPS Estimated At $-0.43

October 14, 2018 - By Marguerite Chambers

Investors sentiment increased to 4.44 in 2018 Q2. Its up 1.44, from 3 in 2018Q1. It increased, as 5 investors sold Aldeyra Therapeutics, Inc. shares while 4 reduced holdings. 21 funds opened positions while 19 raised stakes. 23.78 million shares or 131.37% more from 10.28 million shares in 2018Q1 were reported.
Peddock Capital Limited Company reported 752 shares. Prelude Management Lc reported 21,415 shares. Deutsche National Bank & Trust Ag invested in 25,388 shares. Essex Ltd Limited Liability Company has 39,215 shares. Blackrock holds 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 780,744 shares. Falcon Point Capital Limited Liability has 0.05% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Kepos Lp reported 188,850 shares or 0.08% of all its holdings. Adage Ptnrs Gp Limited Liability Com has invested 0.01% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Weiss Multi holds 40,200 shares or 0.01% of its portfolio. Drw Lc has invested 0.01% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Northern Tru reported 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Ameritas Investment Prtnrs Inc reported 1,388 shares. Morgan Stanley has 42,772 shares for 0% of their portfolio. Mangrove holds 0.22% or 434,344 shares in its portfolio. Fmr Ltd Liability Corp reported 1.61 million shares.

Analysts expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to report $-0.43 EPS on November, 8.They anticipate $0.11 EPS change or 34.38 % from last quarter’s $-0.32 EPS. After having $-0.46 EPS previously, Aldeyra Therapeutics, Inc.’s analysts see -6.52 % EPS growth. The stock increased 5.40% or $0.64 during the last trading session, reaching $12.49. About 675,099 shares traded or 5.96% up from the average. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 41.59% since October 14, 2017 and is uptrending. It has outperformed by 25.97% the S&P500.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 3 analysts covering Aldeyra Therapeutics (NASDAQ:ALDX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics had 4 analyst reports since May 15, 2018 according to SRatingsIntel. Stifel Nicolaus maintained it with “Buy” rating and $36 target in Wednesday, September 26 report. Cantor Fitzgerald maintained it with “Buy” rating and $2300 target in Tuesday, May 15 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, June 26.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $327.55 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

More recent Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) news were published by: Seekingalpha.com which released: “Aldeyra Therapeutics prices common stock offering” on September 28, 2018. Also Seekingalpha.com published the news titled: “Aldeyra +43%; Canaccord sees another 150% upside” on September 26, 2018. Seekingalpha.com‘s news article titled: “Aldeyra’s ganetespib shows positive effect in mesothelioma study; shares ahead 5% premarket” with publication date: September 25, 2018 was also an interesting one.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>